Vancomycin-resistant enterococci (VRE) screening and isolation in the general medicine ward: a cost-effectiveness analysis

Table 3 Incremental cost-effectiveness ratios for VRE screening and isolation program in various scenarios

Scenario	Incremental Cost	Incremental QALYs	ICER ($/QALY)	Probability of CE (at $7500/QALY)	Probability of CE (at $50,000/QALY)
VRE Prevalence in-hospital, 10x (outbreak)	122.79	0.0525	2340	0.545	0.556^a
Room costs excluded ($0)	20.58	0.0077	2682	0.506	0.508^a
Number of beds in ward [33]	109.78	0.0093	11,812	0.505	0.518^a
Program length (5000 admissions)	113.05	0.0023	50,094	0.457	0.499^a
Isolation, decreased effectiveness (0.75)	99.52	0.0002	510,676	0.458	0.476^a
Time horizon, 1 year	109.61	0.0001	856,297	0	0.259
Universal screening VRE screening and isolation	151.44	−0.0039	Dominated	0.484	0.500^a
VRE Prevalence in-hospital, 0.5x	108.41	−0.0112	Dominated	0.479	0.501^a

^aSignifies asymptote at that probability at $50,000/QALY
CE cost-effectiveness, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, VRE vancomycin-resistant enterococci

ISSN: 2047-2994